| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | benzodiazepine receptor activity | 4.20e-05 | 11 | 18 | 2 | GO:0008503 | |
| GeneOntologyMolecularFunction | GABA-gated chloride ion channel activity | 1.16e-04 | 18 | 18 | 2 | GO:0022851 | |
| GeneOntologyMolecularFunction | GABA-A receptor activity | 1.30e-04 | 19 | 18 | 2 | GO:0004890 | |
| GeneOntologyMolecularFunction | ATP-dependent activity | 1.66e-04 | 614 | 18 | 5 | GO:0140657 | |
| GeneOntologyMolecularFunction | GABA receptor activity | 1.75e-04 | 22 | 18 | 2 | GO:0016917 | |
| GeneOntologyMolecularFunction | MHC class I protein binding | 3.75e-04 | 32 | 18 | 2 | GO:0042288 | |
| GeneOntologyMolecularFunction | ligand-gated monoatomic anion channel activity | 9.16e-04 | 50 | 18 | 2 | GO:0099095 | |
| GeneOntologyMolecularFunction | transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | 1.19e-03 | 57 | 18 | 2 | GO:1904315 | |
| GeneOntologyMolecularFunction | MHC protein binding | 1.23e-03 | 58 | 18 | 2 | GO:0042287 | |
| GeneOntologyMolecularFunction | neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential | 1.32e-03 | 60 | 18 | 2 | GO:0099529 | |
| GeneOntologyMolecularFunction | transmitter-gated channel activity | 1.54e-03 | 65 | 18 | 2 | GO:0022835 | |
| GeneOntologyMolecularFunction | transmitter-gated monoatomic ion channel activity | 1.54e-03 | 65 | 18 | 2 | GO:0022824 | |
| GeneOntologyMolecularFunction | cell adhesion molecule binding | 1.75e-03 | 599 | 18 | 4 | GO:0050839 | |
| GeneOntologyMolecularFunction | postsynaptic neurotransmitter receptor activity | 2.05e-03 | 75 | 18 | 2 | GO:0098960 | |
| GeneOntologyMolecularFunction | extracellular ligand-gated monoatomic ion channel activity | 2.16e-03 | 77 | 18 | 2 | GO:0005230 | |
| GeneOntologyMolecularFunction | chloride channel activity | 2.68e-03 | 86 | 18 | 2 | GO:0005254 | |
| GeneOntologyMolecularFunction | cadherin binding | 3.28e-03 | 339 | 18 | 3 | GO:0045296 | |
| GeneOntologyMolecularFunction | neurotransmitter receptor activity | 3.61e-03 | 100 | 18 | 2 | GO:0030594 | |
| GeneOntologyMolecularFunction | monoatomic anion channel activity | 3.82e-03 | 103 | 18 | 2 | GO:0005253 | |
| GeneOntologyMolecularFunction | calcium ion binding | 3.95e-03 | 749 | 18 | 4 | GO:0005509 | |
| GeneOntologyMolecularFunction | ATPase-coupled transmembrane transporter activity | 4.27e-03 | 109 | 18 | 2 | GO:0042626 | |
| GeneOntologyMolecularFunction | transporter activity | 4.69e-03 | 1289 | 18 | 5 | GO:0005215 | |
| GeneOntologyMolecularFunction | beta-catenin binding | 5.15e-03 | 120 | 18 | 2 | GO:0008013 | |
| GeneOntologyMolecularFunction | chloride transmembrane transporter activity | 5.57e-03 | 125 | 18 | 2 | GO:0015108 | |
| GeneOntologyMolecularFunction | ATP-dependent activity, acting on DNA | 5.74e-03 | 127 | 18 | 2 | GO:0008094 | |
| GeneOntologyMolecularFunction | monoatomic ion channel activity | 7.62e-03 | 459 | 18 | 3 | GO:0005216 | |
| GeneOntologyMolecularFunction | monoatomic anion transmembrane transporter activity | 8.03e-03 | 151 | 18 | 2 | GO:0008509 | |
| GeneOntologyMolecularFunction | inorganic anion transmembrane transporter activity | 1.02e-02 | 171 | 18 | 2 | GO:0015103 | |
| GeneOntologyMolecularFunction | channel activity | 1.10e-02 | 525 | 18 | 3 | GO:0015267 | |
| GeneOntologyMolecularFunction | primary active transmembrane transporter activity | 1.10e-02 | 178 | 18 | 2 | GO:0015399 | |
| GeneOntologyMolecularFunction | passive transmembrane transporter activity | 1.10e-02 | 526 | 18 | 3 | GO:0022803 | |
| GeneOntologyMolecularFunction | ligand-gated monoatomic ion channel activity | 1.28e-02 | 193 | 18 | 2 | GO:0015276 | |
| GeneOntologyMolecularFunction | lipid transporter activity | 1.32e-02 | 196 | 18 | 2 | GO:0005319 | |
| GeneOntologyMolecularFunction | ligand-gated channel activity | 1.34e-02 | 197 | 18 | 2 | GO:0022834 | |
| GeneOntologyMolecularFunction | modification-dependent protein binding | 1.45e-02 | 206 | 18 | 2 | GO:0140030 | |
| GeneOntologyMolecularFunction | protein phosphatase binding | 1.51e-02 | 210 | 18 | 2 | GO:0019903 | |
| GeneOntologyCellularComponent | GABA-A receptor complex | 1.19e-04 | 19 | 18 | 2 | GO:1902711 | |
| GeneOntologyCellularComponent | GABA receptor complex | 1.46e-04 | 21 | 18 | 2 | GO:1902710 | |
| GeneOntologyCellularComponent | catenin complex | 3.42e-04 | 32 | 18 | 2 | GO:0016342 | |
| GeneOntologyCellularComponent | GABA-ergic synapse | 3.55e-04 | 164 | 18 | 3 | GO:0098982 | |
| GeneOntologyCellularComponent | adherens junction | 7.50e-04 | 212 | 18 | 3 | GO:0005912 | |
| GeneOntologyCellularComponent | transmembrane transporter complex | 8.97e-04 | 523 | 18 | 4 | GO:1902495 | |
| GeneOntologyCellularComponent | dendrite membrane | 1.05e-03 | 56 | 18 | 2 | GO:0032590 | |
| GeneOntologyCellularComponent | transporter complex | 1.08e-03 | 550 | 18 | 4 | GO:1990351 | |
| GeneOntologyCellularComponent | chloride channel complex | 1.09e-03 | 57 | 18 | 2 | GO:0034707 | |
| GeneOntologyCellularComponent | membrane protein complex | 1.17e-03 | 1498 | 18 | 6 | GO:0098796 | |
| GeneOntologyCellularComponent | neuron projection membrane | 2.23e-03 | 82 | 18 | 2 | GO:0032589 | |
| GeneOntologyCellularComponent | somatodendritic compartment | 3.12e-03 | 1228 | 18 | 5 | GO:0036477 | |
| GeneOntologyCellularComponent | lysosomal lumen | 3.17e-03 | 98 | 18 | 2 | GO:0043202 | |
| GeneOntologyCellularComponent | Golgi lumen | 3.90e-03 | 109 | 18 | 2 | GO:0005796 | |
| GeneOntologyCellularComponent | monoatomic ion channel complex | 3.91e-03 | 378 | 18 | 3 | GO:0034702 | |
| GeneOntologyCellularComponent | photoreceptor outer segment | 4.04e-03 | 111 | 18 | 2 | GO:0001750 | |
| GeneOntologyCellularComponent | dendrite | 5.44e-03 | 858 | 18 | 4 | GO:0030425 | |
| GeneOntologyCellularComponent | dendritic tree | 5.49e-03 | 860 | 18 | 4 | GO:0097447 | |
| GeneOntologyCellularComponent | extrinsic component of plasma membrane | 6.09e-03 | 137 | 18 | 2 | GO:0019897 | |
| GeneOntologyCellularComponent | photoreceptor cell cilium | 6.26e-03 | 139 | 18 | 2 | GO:0097733 | |
| GeneOntologyCellularComponent | presynaptic active zone | 6.44e-03 | 141 | 18 | 2 | GO:0048786 | |
| GeneOntologyCellularComponent | 9+0 non-motile cilium | 7.54e-03 | 153 | 18 | 2 | GO:0097731 | |
| GeneOntologyCellularComponent | cell leading edge | 8.49e-03 | 500 | 18 | 3 | GO:0031252 | |
| GeneOntologyCellularComponent | vacuolar lumen | 1.01e-02 | 178 | 18 | 2 | GO:0005775 | |
| GeneOntologyCellularComponent | non-motile cilium | 1.21e-02 | 196 | 18 | 2 | GO:0097730 | |
| Domain | GABBAg_rcpt | 2.63e-06 | 3 | 18 | 2 | IPR005437 | |
| Domain | Plakophilin/d_Catenin | 1.84e-05 | 7 | 18 | 2 | IPR028435 | |
| Domain | GABAA/Glycine_rcpt | 2.19e-04 | 23 | 18 | 2 | IPR006028 | |
| Domain | Arm | 4.01e-04 | 31 | 18 | 2 | PF00514 | |
| Domain | ARM | 6.70e-04 | 40 | 18 | 2 | SM00185 | |
| Domain | ARM_REPEAT | 6.70e-04 | 40 | 18 | 2 | PS50176 | |
| Domain | Neurotransmitter_ion_chnl_CS | 8.47e-04 | 45 | 18 | 2 | IPR018000 | |
| Domain | Neur_chan_memb | 8.85e-04 | 46 | 18 | 2 | PF02932 | |
| Domain | Neur_chan_LBD | 9.24e-04 | 47 | 18 | 2 | PF02931 | |
| Domain | Neur_channel | 9.24e-04 | 47 | 18 | 2 | IPR006201 | |
| Domain | Neur_chan_lig-bd | 9.24e-04 | 47 | 18 | 2 | IPR006202 | |
| Domain | Armadillo | 9.24e-04 | 47 | 18 | 2 | IPR000225 | |
| Domain | NEUROTR_ION_CHANNEL | 9.24e-04 | 47 | 18 | 2 | PS00236 | |
| Domain | Neurotrans-gated_channel_TM | 9.24e-04 | 47 | 18 | 2 | IPR006029 | |
| Domain | - | 9.24e-04 | 47 | 18 | 2 | 2.70.170.10 | |
| Domain | ARM-type_fold | 3.95e-03 | 339 | 18 | 3 | IPR016024 | |
| Domain | ASX_HYDROXYL | 4.11e-03 | 100 | 18 | 2 | PS00010 | |
| Domain | EGF-type_Asp/Asn_hydroxyl_site | 4.60e-03 | 106 | 18 | 2 | IPR000152 | |
| Domain | Cadherin_CS | 4.86e-03 | 109 | 18 | 2 | IPR020894 | |
| Domain | Cadherin | 5.21e-03 | 113 | 18 | 2 | PF00028 | |
| Domain | CADHERIN_1 | 5.21e-03 | 113 | 18 | 2 | PS00232 | |
| Domain | CADHERIN_2 | 5.30e-03 | 114 | 18 | 2 | PS50268 | |
| Domain | - | 5.30e-03 | 114 | 18 | 2 | 2.60.40.60 | |
| Domain | CA | 5.39e-03 | 115 | 18 | 2 | SM00112 | |
| Domain | Cadherin-like | 5.48e-03 | 116 | 18 | 2 | IPR015919 | |
| Domain | Cadherin | 5.67e-03 | 118 | 18 | 2 | IPR002126 | |
| Domain | EGF | 6.44e-03 | 126 | 18 | 2 | PF00008 | |
| Domain | P-loop_NTPase | 7.75e-03 | 848 | 18 | 4 | IPR027417 | |
| Domain | AAA+_ATPase | 8.33e-03 | 144 | 18 | 2 | IPR003593 | |
| Domain | AAA | 8.33e-03 | 144 | 18 | 2 | SM00382 | |
| Pathway | REACTOME_REGULATION_OF_CDH19_EXPRESSION_AND_FUNCTION | 2.21e-05 | 7 | 15 | 2 | M48017 | |
| Pathway | WP_GABA_RECEPTOR_SIGNALING | 4.83e-04 | 31 | 15 | 2 | M39369 | |
| Pathway | REACTOME_REGULATION_OF_HOMOTYPIC_CELL_CELL_ADHESION | 5.15e-04 | 32 | 15 | 2 | M48012 | |
| Pathway | WP_MBDNF_AND_PROBDNF_REGULATION_OF_GABA_NEUROTRANSMISSION | 7.27e-04 | 38 | 15 | 2 | M39854 | |
| Pubmed | Postsynaptic clustering of gamma-aminobutyric acid type A receptors by the gamma3 subunit in vivo. | 2.53e-07 | 2 | 18 | 2 | 10536013 | |
| Pubmed | 7.59e-07 | 3 | 18 | 2 | 19019179 | ||
| Pubmed | 1.52e-06 | 4 | 18 | 2 | 11948245 | ||
| Pubmed | 1.52e-06 | 4 | 18 | 2 | 10725230 | ||
| Pubmed | 2.53e-06 | 5 | 18 | 2 | 12574411 | ||
| Pubmed | A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. | 3.36e-06 | 205 | 18 | 4 | 12040188 | |
| Pubmed | 3.79e-06 | 6 | 18 | 2 | 9682826 | ||
| Pubmed | 5.30e-06 | 7 | 18 | 2 | 25009281 | ||
| Pubmed | Arvcf Dependent Adherens Junction Stability is Required to Prevent Age-Related Cortical Cataracts. | 7.07e-06 | 8 | 18 | 2 | 35874813 | |
| Pubmed | 7.07e-06 | 8 | 18 | 2 | 11821434 | ||
| Pubmed | 1.14e-05 | 10 | 18 | 2 | 20583128 | ||
| Pubmed | 1.39e-05 | 11 | 18 | 2 | 39137998 | ||
| Pubmed | 1.66e-05 | 12 | 18 | 2 | 22318628 | ||
| Pubmed | The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. | 2.29e-05 | 14 | 18 | 2 | 22144466 | |
| Pubmed | 3.85e-05 | 18 | 18 | 2 | 18985723 | ||
| Pubmed | 3.85e-05 | 18 | 18 | 2 | 19078961 | ||
| Pubmed | p120 catenin is required for normal renal tubulogenesis and glomerulogenesis. | 4.30e-05 | 19 | 18 | 2 | 21521738 | |
| Pubmed | 4.87e-05 | 405 | 18 | 4 | 38187761 | ||
| Pubmed | 5.81e-05 | 22 | 18 | 2 | 38794925 | ||
| Pubmed | 6.36e-05 | 23 | 18 | 2 | 25523391 | ||
| Pubmed | A neurogenomics approach to gene expression analysis in the developing brain. | 8.87e-05 | 170 | 18 | 3 | 15582152 | |
| Pubmed | 1.02e-04 | 29 | 18 | 2 | 20167577 | ||
| Pubmed | Gene-smoking interactions identify several novel blood pressure loci in the Framingham Heart Study. | 1.24e-04 | 32 | 18 | 2 | 25189868 | |
| Pubmed | The splicing regulator Rbfox2 is required for both cerebellar development and mature motor function. | 1.32e-04 | 33 | 18 | 2 | 22357600 | |
| Pubmed | Cdc42 controls progenitor cell differentiation and beta-catenin turnover in skin. | 1.85e-04 | 39 | 18 | 2 | 16510873 | |
| Pubmed | 1.95e-04 | 40 | 18 | 2 | 16210410 | ||
| Pubmed | TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1. | 2.26e-04 | 43 | 18 | 2 | 31992359 | |
| Pubmed | 3.56e-04 | 54 | 18 | 2 | 35391932 | ||
| Pubmed | 4.71e-04 | 300 | 18 | 3 | 19086053 | ||
| Pubmed | 5.00e-04 | 64 | 18 | 2 | 22261194 | ||
| Interaction | CTNNA3 interactions | 2.80e-06 | 114 | 18 | 4 | int:CTNNA3 | |
| Interaction | TACR1 interactions | 3.02e-05 | 69 | 18 | 3 | int:TACR1 | |
| GeneFamily | Gamma-aminobutyric acid type A receptor subunits | 9.45e-05 | 19 | 14 | 2 | 563 | |
| GeneFamily | Armadillo repeat containing|Protein phosphatase 1 regulatory subunits | 4.94e-04 | 43 | 14 | 2 | 409 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_500 | 3.96e-05 | 482 | 18 | 5 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_500 | |
| CoexpressionAtlas | dev gonad_e13.5_M_InterstitFLeydig_MafB_k-means-cluster#3_top-relative-expression-ranked_1000 | 1.58e-04 | 336 | 18 | 4 | gudmap_dev gonad_e13.5_M_InterstitFLeydig_MafB_k3_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_1000_k-means-cluster#3 | 1.64e-04 | 339 | 18 | 4 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_1000_K3 | |
| CoexpressionAtlas | dev gonad_e12.5_M_InterstitTestis_Sma_top-relative-expression-ranked_200 | 2.76e-04 | 153 | 18 | 3 | gudmap_dev gonad_e12.5_M_InterstitTestis_Sma_200 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Floor Plate_top-relative-expression-ranked_2500_k-means-cluster#2 | 2.93e-04 | 395 | 18 | 4 | Facebase_RNAseq_e8.5_Floor Plate_2500_K2 | |
| CoexpressionAtlas | DevelopingKidney_e15.5_Pelvic Mesenchyme_emap-8241_top-relative-expression-ranked_200 | 3.39e-04 | 164 | 18 | 3 | gudmap_developingKidney_e15.5_Pelvic Mesenchyme_200 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_1000_k-means-cluster#2 | 3.96e-04 | 173 | 18 | 3 | Facebase_RNAseq_e10.5_Maxillary Arch_1000_K2 | |
| CoexpressionAtlas | dev gonad_e11.5_F_GonadVasMes_Flk_k-means-cluster#1_top-relative-expression-ranked_200 | 4.44e-04 | 37 | 18 | 2 | gudmap_dev gonad_e11.5_F_GonadVasMes_Flk_k1_200 | |
| CoexpressionAtlas | mendel_RNAseq_e12.5_Urothelium_ShhCreRFP_2500_K4 | 5.46e-04 | 41 | 18 | 2 | mendel_RNAseq_e12.5_Urothelium_ShhCreRFP_2500_K4 | |
| CoexpressionAtlas | dev gonad_e12.5_M_InterstitTestis_Sma_k-means-cluster#4_top-relative-expression-ranked_200 | 5.73e-04 | 42 | 18 | 2 | gudmap_dev gonad_e12.5_M_InterstitTestis_Sma_k4_200 | |
| CoexpressionAtlas | kidney_P1_CapMes_Crym_k-means-cluster#4_top-relative-expression-ranked_100 | 6.00e-04 | 43 | 18 | 2 | gudmap_kidney_P1_CapMes_Crym_k4_100 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_500 | 6.09e-04 | 479 | 18 | 4 | Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_500 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Hind Brain Neural Epithelium_top-relative-expression-ranked_2500_k-means-cluster#5 | 6.50e-04 | 205 | 18 | 3 | Facebase_RNAseq_e8.5_Hind Brain Neural Epithelium_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_500 | 6.94e-04 | 496 | 18 | 4 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_500 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Olfactory Placode_top-relative-expression-ranked_1000_k-means-cluster#2 | 6.97e-04 | 210 | 18 | 3 | Facebase_RNAseq_e9.5_Olfactory Placode_1000_K2 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_1000_k-means-cluster#1 | 9.42e-04 | 233 | 18 | 3 | Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_1000_K1 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_1000 | 1.01e-03 | 967 | 18 | 5 | Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_1000_k-means-cluster#4 | 1.04e-03 | 241 | 18 | 3 | Facebase_RNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_1000_K4 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Olfactory Placode_top-relative-expression-ranked_1000 | 1.04e-03 | 973 | 18 | 5 | Facebase_RNAseq_e9.5_Olfactory Placode_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_1000 | 1.05e-03 | 976 | 18 | 5 | Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_1000 | 1.07e-03 | 979 | 18 | 5 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_1000 | 1.10e-03 | 986 | 18 | 5 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_1000_k-means-cluster#2 | 1.13e-03 | 248 | 18 | 3 | Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_1000_K2 | |
| CoexpressionAtlas | kidney_P1_CapMes_Crym_top-relative-expression-ranked_100 | 1.25e-03 | 62 | 18 | 2 | gudmap_kidney_P1_CapMes_Crym_100 | |
| CoexpressionAtlas | kidney_P0_CapMes_Crym_top-relative-expression-ranked_100 | 1.29e-03 | 63 | 18 | 2 | gudmap_kidney_P0_CapMes_Crym_100 | |
| ToppCell | pdx|World / Sample and Cell Type and Tumor Cluster (all cells) | 8.27e-07 | 186 | 18 | 4 | de8e538c8767d41b8a52f5e58ba1affd4e7244c4 | |
| ToppCell | pdx-Tumor_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 8.27e-07 | 186 | 18 | 4 | 0b88a87158a9ca8de3bf40a4ff1687150707a5f0 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.00e-07 | 190 | 18 | 4 | 45df8fee00f8949937863159d7aa042e72748d9b | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 9.78e-07 | 194 | 18 | 4 | 011e14d9ed1393275f892060e7708ffadcd0767f | |
| ToppCell | Neuron-Postmitotic-Inhibitory_Neuron-MGE2|World / Primary Cells by Cluster | 9.78e-07 | 194 | 18 | 4 | b42fd64b0fb95434a9e4e6586f31d26114a4074b | |
| ToppCell | Neuron-Postmitotic-Inhibitory_Neuron-MGE2-10|World / Primary Cells by Cluster | 9.78e-07 | 194 | 18 | 4 | 81e7bc6516ab8d02ccd1c76a56a3533b788c27c8 | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA----L1-6|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.10e-06 | 200 | 18 | 4 | 310cd53db1c137f6af74e6ae682221d7ac27310c | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.10e-06 | 200 | 18 | 4 | c24a3099e3d96d8b72f6d05286bb355d661a0377 | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA---|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.10e-06 | 200 | 18 | 4 | 4fc3de4bff7ed2bf40b38462c4b4e9b87af6a4ca | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA-|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.10e-06 | 200 | 18 | 4 | f17b5a54e8f9eba9dcd0808ba4e8d275ac41bce2 | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA--|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.10e-06 | 200 | 18 | 4 | cc3409518f8b436ea92deb955e81114b3f410ff7 | |
| ToppCell | Macroglial-Polydendrocytes|Macroglial / cells hierarchy compared to all cells using T-Statistic | 1.10e-06 | 200 | 18 | 4 | 961858738ce35db8760c8c2e136f8369bc444ccf | |
| ToppCell | Neuronal-Inhibitory-iB|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.10e-06 | 200 | 18 | 4 | 45ddc5ef2caa87ada88327b63ba9b150a6bb3aa5 | |
| ToppCell | COVID-19-kidney-Mito-rich_Int|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.54e-05 | 122 | 18 | 3 | a4220adb4e6055a599bd9bbf65d460fc4e68b543 | |
| ToppCell | COVID-19-kidney-Mito-rich_Int|kidney / Disease (COVID-19 only), tissue and cell type | 1.82e-05 | 129 | 18 | 3 | 57b705106aec7bbfc587de1ccd4f2335fc44dd6f | |
| ToppCell | COVID-19-kidney-Epithelial_(EC)|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.99e-05 | 133 | 18 | 3 | a8abb6b54862123961ae6defbf251ee6e9575258 | |
| ToppCell | COVID-19-kidney-Technical/muscle_(EC)|kidney / Disease (COVID-19 only), tissue and cell type | 2.28e-05 | 139 | 18 | 3 | 64c35411bbe67acb5010dadc4b0b1be0f8b17737 | |
| ToppCell | COVID-19-kidney-Technical/muscle|kidney / Disease (COVID-19 only), tissue and cell type | 2.74e-05 | 148 | 18 | 3 | 0dbd87078f54ee1c2f8ec64e8bac9dfddb9c181e | |
| ToppCell | COVID-19-kidney-Technical/muscle_(Mes)|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.74e-05 | 148 | 18 | 3 | d6ac5972267254651dfbe16bb4e9a62228093cc7 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-OPC-OPC-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.15e-05 | 155 | 18 | 3 | 77fdae85d36efb776db977eb424b32487ef222e4 | |
| ToppCell | COVID-19-kidney-Technical/muscle_(Mes)|kidney / Disease (COVID-19 only), tissue and cell type | 3.40e-05 | 159 | 18 | 3 | 5335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d | |
| ToppCell | COVID-19-kidney-Technical/muscle_(Imm)|kidney / Disease (COVID-19 only), tissue and cell type | 3.66e-05 | 163 | 18 | 3 | 19c28ce16a588a7f4a035c32726f6ccd67702b5b | |
| ToppCell | 5'-GW_trimst-2-LymphNode-Neuronal-Glial_immature-Glia_1_(DHH+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.45e-05 | 174 | 18 | 3 | 1463c98f8f519dd030587abbdbeb1b4e1bca5dd1 | |
| ToppCell | 5'-GW_trimst-2-LymphNode-Neuronal-Glial_immature|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.45e-05 | 174 | 18 | 3 | c9d4e375dedd2b099a9ed70ec38ff35bbb0ce48a | |
| ToppCell | 5'-GW_trimst-2-LymphNode-Neuronal|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.45e-05 | 174 | 18 | 3 | d421c0069d24cb560a3a429929e3cd1eceaeabcf | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 4.52e-05 | 175 | 18 | 3 | 9a96a946db731ba24c9be34bedebf1f4a1372b9e | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 4.52e-05 | 175 | 18 | 3 | 2b51406a2c2daa13ab4ed283ede038cd11d9e641 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-lymphatic_endothelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 4.52e-05 | 175 | 18 | 3 | 54c1f080195ad8392a095e83b56a4b54073d4c0d | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L2-4_SST_AHR|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.60e-05 | 176 | 18 | 3 | 322259a35f5c97d73ce7f75835dcdb5c954c91f8 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.60e-05 | 176 | 18 | 3 | 66c9c6b59030f67e8d746a9c6930e50923f2ded1 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.60e-05 | 176 | 18 | 3 | b4a23d8d1414434adeb237a96f28c825f1aebd77 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5-6_PVALB_STON2|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.84e-05 | 179 | 18 | 3 | d1365d48d1b017a7917f4f63a82ac4720c3d87df | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5-6_PVALB_STON2|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.08e-05 | 182 | 18 | 3 | a3c5c0eff527c8d3848acda14af8f9e99c69b0de | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.16e-05 | 183 | 18 | 3 | 121791ef84e7ce377ed6f5b7953af8865e04958e | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.25e-05 | 184 | 18 | 3 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.25e-05 | 184 | 18 | 3 | 2cbed6462fea2622871bb7e49b0df3d984239281 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.25e-05 | 184 | 18 | 3 | 2b19a8c5f823e00812908b23e66bb4e563278aff | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-5_PVALB_TRIM67|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.25e-05 | 184 | 18 | 3 | 7f6c8912677764d438ab0555faca344d74c2f483 | |
| ToppCell | wk_20-22-Epithelial-PNS-intermediate_Schwann|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 5.25e-05 | 184 | 18 | 3 | 4e3ba64692868563a579902aa9c6f88cab5bce26 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 5.33e-05 | 185 | 18 | 3 | e58a009aaf342be019a909747b1895d5987d4daf | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.42e-05 | 186 | 18 | 3 | 96f6603cc75fa1ffc2a2fdb94ec0ec09498e540a | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 5.42e-05 | 186 | 18 | 3 | 23b8d51d20b05795a73892d3e20e0f9b6a207820 | |
| ToppCell | Substantia_nigra-Neuronal-Inhibitory|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 5.42e-05 | 186 | 18 | 3 | 9d3efe2a4feea2bc205a7e45b9b9f9ed9b3609ce | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.42e-05 | 186 | 18 | 3 | 6379609b7ace80683f5754b16aa77f11b43766ae | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L2-4_SST_AHR|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.51e-05 | 187 | 18 | 3 | 01393f6d1983eb4a2bcc80252012f77892851679 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.51e-05 | 187 | 18 | 3 | 85f1678338a47d91e296f0620d4887f057eb7e70 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(non-nasal)-Club_(non-nasal)_L.0.4.0.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.51e-05 | 187 | 18 | 3 | f5a202d5f8eb57b57d80815ce98774e04c387383 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.59e-05 | 188 | 18 | 3 | 8de5a07301f9b5984680c873e5a92395b5ed3dd3 | |
| ToppCell | RA-10._Endothelium_II|World / Chamber and Cluster_Paper | 5.68e-05 | 189 | 18 | 3 | 75c248b9de5e2fb7a0baa8cdbab516e575cc4394 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.68e-05 | 189 | 18 | 3 | 78cf414b98bcb19deb934409acddaad1cd51b67f | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-OPC-OPC-G|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.77e-05 | 190 | 18 | 3 | 6c7e1086c0a274cd5527c3104106e372811c9905 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.77e-05 | 190 | 18 | 3 | 26843ec1d19ac85a50990705353b802745d33e4d | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.77e-05 | 190 | 18 | 3 | d19bc44310c53726e2f5f6a2bd377bbbf1d1983f | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Neuronal-ventral_progenitors_and_neurons_1|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type. | 5.77e-05 | 190 | 18 | 3 | 6e92c78799f34b31d098854503c796edb0dc7f80 | |
| ToppCell | COVID-19-Heart-Mito_EC|COVID-19 / Disease (COVID-19 only), tissue and cell type | 5.77e-05 | 190 | 18 | 3 | ea74e0e38bcaba125b48c88331e9ba09228d3178 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L2-4_SST_AHR|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.86e-05 | 191 | 18 | 3 | 782bc7946417549ffd39e5b596db659436fa01ba | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.96e-05 | 192 | 18 | 3 | 67d6230e32d446dcb12047fae2c3f1faa80dd720 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.96e-05 | 192 | 18 | 3 | 0003d7ef9a8e521e70ac33c63aad843d9b6215c2 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.96e-05 | 192 | 18 | 3 | df1545670370fb1010c567cd059c2783eab315f7 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.05e-05 | 193 | 18 | 3 | 53bcd50892c379b2a571751f6eb1062436339fe7 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.05e-05 | 193 | 18 | 3 | e74fdc8718fe0933e1f4dd3fe37e2134983b99b6 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.05e-05 | 193 | 18 | 3 | c7e9e6e4bf5e07c9cbdf1aa7c8828f4b2500e3ff | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.05e-05 | 193 | 18 | 3 | 658c2b30a4d806c5ce78ea4392fe8eb86b8d1e99 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.05e-05 | 193 | 18 | 3 | d1445b8bf2bab36e1a326ddb2a528151db016c7d | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 6.05e-05 | 193 | 18 | 3 | 9f69edc97b868d23998abc98928a2e89a885ef8a | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.05e-05 | 193 | 18 | 3 | 4979862c0c16e6b4baa4c79894f1d237c861f5a5 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.05e-05 | 193 | 18 | 3 | 3ed46f5a7419ec4eddbd0df0d9b5f53aa486198b | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.05e-05 | 193 | 18 | 3 | 5581a5ebcd21a2a8062ccfb917f088ec67a10a9c | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.14e-05 | 194 | 18 | 3 | ae7df037592f1c20c9d32be15fe6fc3c562ebeb1 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 6.14e-05 | 194 | 18 | 3 | cb0422e7607dbd77204428b7e2c70dfe14a6ca11 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.14e-05 | 194 | 18 | 3 | e5990880961d2469759ce4b3b20ae93ace3ebd1f | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.14e-05 | 194 | 18 | 3 | 83863da11dfbe59b2d0a2c08db40b537c150588c | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.14e-05 | 194 | 18 | 3 | 4f758718a1233c25c25d99fc1b7b06f906b8b0a2 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.14e-05 | 194 | 18 | 3 | 02a9cc821c2b14aa7d0e55661a5fab66364474e1 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.14e-05 | 194 | 18 | 3 | 240d122dcb9dd1ab2867503ad85869853adcacae | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.14e-05 | 194 | 18 | 3 | 1bcb3fafd498614f7bac2b1c9b7de56e39110f65 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 6.14e-05 | 194 | 18 | 3 | 71d3c7448b1734de54187f902f65649f9283bd4c | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.24e-05 | 195 | 18 | 3 | 44d7bef5f59c2c2bad1392ee6aabdaa5d7f531d9 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.24e-05 | 195 | 18 | 3 | d9a5c75d31c6e8bb1e1ab7fd115ac5deb5fb1c8d | |
| ToppCell | Tracheal-10x5prime-Stromal-Schwann|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 6.33e-05 | 196 | 18 | 3 | b6226163d9fc93ecfff2115bb74408303a000490 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-OPC|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 6.33e-05 | 196 | 18 | 3 | 671c380b58d7f634b4fbec38c357d357ea4f3535 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.33e-05 | 196 | 18 | 3 | ba869f7a86f37fd6d84d6ad69baca0e0faaf5887 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 6.33e-05 | 196 | 18 | 3 | 1450cb69c5bf469e97c03bf1890f6f7c54165b8a | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.33e-05 | 196 | 18 | 3 | 7af6c5147ac859353504d19727dbe24f63a29dd4 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.33e-05 | 196 | 18 | 3 | 30ad56d49000e4ddce73b4443b3994564bd1e2d6 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.33e-05 | 196 | 18 | 3 | 676c56b44ac29f7baecb62f49bb8597cc74c0a88 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-OPC-OPC|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 6.33e-05 | 196 | 18 | 3 | f374cb3ec31c6eef2cef9e07547bfd1e380553af | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Deep_Layer-37|World / Primary Cells by Cluster | 6.43e-05 | 197 | 18 | 3 | 00d756bc0231e1b3b88430214338c1059cb11106 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.43e-05 | 197 | 18 | 3 | b349f8e96d61a4c296af64711e11fc44459a9413 | |
| ToppCell | 10x_3'_v3-tissue-resident_(10x_3'_v3)-myeloid-myeloid_monocytic|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 6.43e-05 | 197 | 18 | 3 | 7870c0651caefb0ed13d9f9dab43b5f24d6a9efc | |
| ToppCell | PCW_13-14-Mesenchymal|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 6.43e-05 | 197 | 18 | 3 | 73a2085d2682d636726a5432d572ae2a3fbe1c3f | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Layer_VI_Pan-area-33|World / Primary Cells by Cluster | 6.43e-05 | 197 | 18 | 3 | d20f29088e9afd8a960d6f680075c380e550f8a7 | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Layer_VI_Pan-area|World / Primary Cells by Cluster | 6.43e-05 | 197 | 18 | 3 | 79b9e7f2e8e33b3c547f716be5667156c48b0dfc | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.43e-05 | 197 | 18 | 3 | 6d027119a5f7ca2aac1b10837e43f9a2bb54db85 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.43e-05 | 197 | 18 | 3 | c2e390653d5dee7e731c1840cfdab41987dede9b | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.52e-05 | 198 | 18 | 3 | 6d18b45eda4014759e6dd282d78ffd28df8a6044 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.52e-05 | 198 | 18 | 3 | c01091ef18e096d792ea2a7a715764a5b215355f | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-OPC-OPC-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 6.52e-05 | 198 | 18 | 3 | 02d0d8a212e09c0962ab1dae6a885d26d357f66a | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.52e-05 | 198 | 18 | 3 | 0ff30edfd3c133a42e8cb96e1631a1143215f808 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 6.52e-05 | 198 | 18 | 3 | 17dc055e2a289496d9c5cdbf3297bdf906dc6d22 | |
| Computational | Ion channels. | 3.95e-04 | 27 | 12 | 2 | MODULE_214 | |
| Drug | delta-aminovaleric acid | 6.58e-06 | 47 | 18 | 3 | CID000000138 | |
| Drug | Indapamide [26807-65-8]; Up 200; 10.6uM; HL60; HT_HG-U133A | 1.51e-05 | 197 | 18 | 4 | 2361_UP | |
| Drug | Naphazoline hydrochloride [550-99-2]; Up 200; 16.2uM; PC3; HT_HG-U133A | 1.54e-05 | 198 | 18 | 4 | 6604_UP | |
| Drug | Rifampicin [13292-46-1]; Up 200; 4.8uM; PC3; HT_HG-U133A | 1.57e-05 | 199 | 18 | 4 | 4008_UP | |
| Drug | 7-ketocholesterol | 1.60e-05 | 63 | 18 | 3 | CID000091474 | |
| Drug | pH Q | 3.16e-05 | 79 | 18 | 3 | CID000007708 | |
| Drug | Bu-1014 | 3.23e-05 | 11 | 18 | 2 | CID015942721 | |
| Drug | fosazepam | 3.23e-05 | 11 | 18 | 2 | CID000037114 | |
| Drug | Zapizolam | 3.23e-05 | 11 | 18 | 2 | CID000068832 | |
| Drug | C19H18ClN3O | 3.23e-05 | 11 | 18 | 2 | CID000027452 | |
| Drug | flutoprazepam | 3.23e-05 | 11 | 18 | 2 | CID000003400 | |
| Drug | Reclazepam | 3.23e-05 | 11 | 18 | 2 | CID003052777 | |
| Drug | iclazepam | 3.23e-05 | 11 | 18 | 2 | CID000068777 | |
| Drug | Arfendazam | 3.23e-05 | 11 | 18 | 2 | CID000065803 | |
| Drug | menitrazepam | 3.23e-05 | 11 | 18 | 2 | CID000189875 | |
| Drug | Serin hydrazid | 3.23e-05 | 11 | 18 | 2 | CID000041637 | |
| Drug | sulazepam | 3.23e-05 | 11 | 18 | 2 | CID000017931 | |
| Drug | elfazepam | 3.23e-05 | 11 | 18 | 2 | CID000065445 | |
| Drug | camazepam | 3.23e-05 | 11 | 18 | 2 | CID000037367 | |
| Drug | uldazepam | 3.23e-05 | 11 | 18 | 2 | CID000034274 | |
| Drug | gidazepam | 3.23e-05 | 11 | 18 | 2 | CID000121919 | |
| Drug | triflubazam | 3.23e-05 | 11 | 18 | 2 | CID000031157 | |
| Drug | fletazepam | 3.23e-05 | 11 | 18 | 2 | CID000036834 | |
| Drug | SB-205384 | 3.88e-05 | 12 | 18 | 2 | CID000197690 | |
| Drug | U-93631 | 3.88e-05 | 12 | 18 | 2 | CID000197626 | |
| Drug | haloxazolam | 3.88e-05 | 12 | 18 | 2 | CID000003563 | |
| Drug | pivoxazepam | 3.88e-05 | 12 | 18 | 2 | CID000068722 | |
| Drug | razobazam | 3.88e-05 | 12 | 18 | 2 | CID000071228 | |
| Drug | doxefazepam | 3.88e-05 | 12 | 18 | 2 | CID000038668 | |
| Drug | cinolazepam | 4.58e-05 | 13 | 18 | 2 | CID003033621 | |
| Drug | AC1MVFYM | 4.58e-05 | 13 | 18 | 2 | CID003707225 | |
| Drug | nerisopam | 4.58e-05 | 13 | 18 | 2 | CID000065875 | |
| Drug | flutazolam | 4.58e-05 | 13 | 18 | 2 | CID000003398 | |
| Drug | alpha IMGBL | 4.58e-05 | 13 | 18 | 2 | CID000131516 | |
| Drug | 4-PIOL | 4.58e-05 | 13 | 18 | 2 | CID000125520 | |
| Drug | Ro 11-3128 | 4.58e-05 | 13 | 18 | 2 | CID000093364 | |
| Drug | metaclazepam | 4.58e-05 | 13 | 18 | 2 | CID000071272 | |
| Drug | Me-lex | 5.34e-05 | 14 | 18 | 2 | CID000004177 | |
| Drug | beta-CCt | 5.34e-05 | 14 | 18 | 2 | CID000124514 | |
| Drug | ethyl loflazepate | 5.34e-05 | 14 | 18 | 2 | CID000003299 | |
| Drug | loprazolam | 6.16e-05 | 15 | 18 | 2 | CID003033860 | |
| Drug | SR 95103 | 6.16e-05 | 15 | 18 | 2 | CID000125958 | |
| Drug | premazepam | 6.16e-05 | 15 | 18 | 2 | CID000072104 | |
| Drug | pinazepam | 6.16e-05 | 15 | 18 | 2 | CID000040391 | |
| Drug | fludiazepam | 6.16e-05 | 15 | 18 | 2 | CID000003369 | |
| Drug | TBOB | 6.16e-05 | 15 | 18 | 2 | CID000114986 | |
| Drug | girisopam | 6.16e-05 | 15 | 18 | 2 | CID000071257 | |
| Drug | P858 | 7.04e-05 | 16 | 18 | 2 | CID000004617 | |
| Drug | tetrazepam | 7.04e-05 | 16 | 18 | 2 | CID000025215 | |
| Drug | Ro 19-4603 | 7.04e-05 | 16 | 18 | 2 | CID000127382 | |
| Drug | nimetazepam | 7.04e-05 | 16 | 18 | 2 | CID000004496 | |
| Drug | dihydroxyaflavinine | 7.97e-05 | 17 | 18 | 2 | CID000156857 | |
| Drug | CL 218,872 | 7.97e-05 | 17 | 18 | 2 | CID000107950 | |
| Drug | abecarnil | 8.96e-05 | 18 | 18 | 2 | CID000065914 | |
| Drug | cloxazolam | 8.96e-05 | 18 | 18 | 2 | CID000002816 | |
| Drug | clorazepate | 8.96e-05 | 18 | 18 | 2 | CID000002809 | |
| Drug | phenazepam | 8.96e-05 | 18 | 18 | 2 | CID000040113 | |
| Drug | lormetazepam | 8.96e-05 | 18 | 18 | 2 | CID000013314 | |
| Drug | etifoxine | 1.00e-04 | 19 | 18 | 2 | CID000030768 | |
| Drug | ZK 93426 | 1.00e-04 | 19 | 18 | 2 | CID000115210 | |
| Drug | AC1N65YL | 1.11e-04 | 20 | 18 | 2 | CID004229818 | |
| Drug | halazepam | 1.11e-04 | 20 | 18 | 2 | CID000031640 | |
| Drug | Ro 15-4513 | 1.11e-04 | 20 | 18 | 2 | CID000005081 | |
| Drug | EBOB | 1.11e-04 | 20 | 18 | 2 | CID000115223 | |
| Drug | prazepam | 1.23e-04 | 21 | 18 | 2 | CID000004890 | |
| Drug | R 5135 | 1.23e-04 | 21 | 18 | 2 | CID000119544 | |
| Drug | bicuculline methochloride | 1.23e-04 | 21 | 18 | 2 | CID000123659 | |
| Drug | Iomazenil (123I | 1.35e-04 | 22 | 18 | 2 | CID000065959 | |
| Drug | quazepam | 1.35e-04 | 22 | 18 | 2 | CID000004999 | |
| Drug | imidazenil | 1.35e-04 | 22 | 18 | 2 | CID000119194 | |
| Drug | etizolam | 1.35e-04 | 22 | 18 | 2 | CID000003307 | |
| Drug | 6 mEq | 1.35e-04 | 22 | 18 | 2 | CID000126186 | |
| Drug | adinazolam | 1.48e-04 | 23 | 18 | 2 | CID000037632 | |
| Drug | bretazenil | 1.48e-04 | 23 | 18 | 2 | CID000107926 | |
| Drug | zolazepam | 1.48e-04 | 23 | 18 | 2 | CID000035775 | |
| Drug | methohexital | 1.61e-04 | 24 | 18 | 2 | CID000009034 | |
| Drug | gamma-acetylenic GABA | 1.61e-04 | 24 | 18 | 2 | CID000003452 | |
| Drug | medazepam | 1.61e-04 | 24 | 18 | 2 | CID000004041 | |
| Drug | alpidem | 1.61e-04 | 24 | 18 | 2 | CID000054897 | |
| Drug | SL 75102 | 1.61e-04 | 24 | 18 | 2 | CID005751746 | |
| Drug | beta-CCM | 1.61e-04 | 24 | 18 | 2 | CID000107704 | |
| Drug | isonipecotic acid | 1.75e-04 | 25 | 18 | 2 | CID000003773 | |
| Drug | P4-s | 1.75e-04 | 25 | 18 | 2 | CID000004838 | |
| Drug | CCD 1042 | 1.75e-04 | 25 | 18 | 2 | CID000038022 | |
| Drug | beta-CCE | 1.75e-04 | 25 | 18 | 2 | CID000105078 | |
| Drug | benzodiazepine | 1.81e-04 | 142 | 18 | 3 | CID000134664 | |
| Drug | SKF97541 | 1.90e-04 | 26 | 18 | 2 | CID000005230 | |
| Drug | V-X-A | 1.90e-04 | 26 | 18 | 2 | CID006369389 | |
| Drug | pitrazepin | 2.05e-04 | 27 | 18 | 2 | CID000146222 | |
| Drug | chlormethiazole | 2.20e-04 | 28 | 18 | 2 | CID000010783 | |
| Drug | mephobarbital | 2.20e-04 | 28 | 18 | 2 | CID000008271 | |
| Drug | Toluene | 2.28e-04 | 749 | 18 | 5 | ctd:D014050 | |
| Drug | tofisopam | 2.37e-04 | 29 | 18 | 2 | CID000005502 | |
| Drug | etazolate | 2.37e-04 | 29 | 18 | 2 | CID000003277 | |
| Drug | clobazam | 2.37e-04 | 29 | 18 | 2 | CID000002789 | |
| Drug | clotiazepam | 2.37e-04 | 29 | 18 | 2 | CID000002811 | |
| Drug | 3-isothujone | 2.53e-04 | 30 | 18 | 2 | CID000011027 | |
| Drug | guvacine | 2.53e-04 | 30 | 18 | 2 | CID000003532 | |
| Drug | allylglycine | 2.53e-04 | 30 | 18 | 2 | CID000014044 | |
| Drug | SKF89976A | 2.71e-04 | 31 | 18 | 2 | CID000092409 | |
| Disease | Drug habituation | 4.51e-05 | 115 | 18 | 3 | C0013170 | |
| Disease | Substance-Related Disorders | 4.51e-05 | 115 | 18 | 3 | C0236969 | |
| Disease | Drug abuse | 4.51e-05 | 115 | 18 | 3 | C0013146 | |
| Disease | Drug Use Disorders | 4.51e-05 | 115 | 18 | 3 | C0013222 | |
| Disease | Drug Dependence | 4.51e-05 | 115 | 18 | 3 | C1510472 | |
| Disease | Substance Dependence | 4.51e-05 | 115 | 18 | 3 | C0038580 | |
| Disease | Substance Use Disorders | 4.51e-05 | 115 | 18 | 3 | C0038586 | |
| Disease | Organic Mental Disorders, Substance-Induced | 4.51e-05 | 115 | 18 | 3 | C0029231 | |
| Disease | Prescription Drug Abuse | 4.51e-05 | 115 | 18 | 3 | C4316881 | |
| Disease | Substance abuse problem | 4.63e-05 | 116 | 18 | 3 | C0740858 | |
| Disease | autism spectrum disorder (implicated_via_orthology) | 1.03e-04 | 152 | 18 | 3 | DOID:0060041 (implicated_via_orthology) | |
| Disease | carotid artery intima media thickness | 1.38e-04 | 450 | 18 | 4 | EFO_0007117 | |
| Disease | pack-years measurement, systolic blood pressure | 1.95e-04 | 34 | 18 | 2 | EFO_0006335, EFO_0006526 | |
| Disease | alcohol dependence measurement | 5.12e-04 | 55 | 18 | 2 | EFO_0007835 | |
| Disease | triglycerides in LDL measurement | 5.31e-04 | 56 | 18 | 2 | EFO_0022320 | |
| Disease | ovarian cancer (is_implicated_in) | 5.31e-04 | 56 | 18 | 2 | DOID:2394 (is_implicated_in) | |
| Disease | Alcoholic Intoxication, Chronic | 5.46e-04 | 268 | 18 | 3 | C0001973 | |
| Disease | triglycerides in small VLDL measurement | 6.30e-04 | 61 | 18 | 2 | EFO_0022145 | |
| Disease | triglycerides in medium LDL measurement | 6.50e-04 | 62 | 18 | 2 | EFO_0022322 | |
| Disease | triglycerides to total lipids in very large HDL percentage | 6.50e-04 | 62 | 18 | 2 | EFO_0022339 | |
| Disease | triglycerides in small HDL measurement | 6.50e-04 | 62 | 18 | 2 | EFO_0022158 | |
| Disease | phospholipids in large VLDL measurement | 6.50e-04 | 62 | 18 | 2 | EFO_0022169 | |
| Disease | neuroimaging measurement, brain volume measurement | 6.60e-04 | 286 | 18 | 3 | EFO_0004346, EFO_0006930 | |
| Disease | triglycerides in small LDL measurement | 7.15e-04 | 65 | 18 | 2 | EFO_0022323 | |
| Disease | word reading | 7.15e-04 | 65 | 18 | 2 | EFO_0005300 | |
| Disease | daytime rest measurement | 7.22e-04 | 295 | 18 | 3 | EFO_0007828 | |
| Disease | body weight | 7.60e-04 | 1261 | 18 | 5 | EFO_0004338 | |
| Disease | triglycerides in very small VLDL measurement | 7.82e-04 | 68 | 18 | 2 | EFO_0022144 | |
| Disease | Amphetamine-Related Disorders | 9.50e-04 | 75 | 18 | 2 | C0236733 | |
| Disease | Amphetamine Abuse | 9.50e-04 | 75 | 18 | 2 | C0236807 | |
| Disease | Amphetamine Addiction | 9.50e-04 | 75 | 18 | 2 | C0236804 | |
| Disease | response to alcohol | 9.50e-04 | 75 | 18 | 2 | EFO_0005526 | |
| Disease | risk-taking behaviour | 1.02e-03 | 764 | 18 | 4 | EFO_0008579 | |
| Disease | executive function measurement | 1.45e-03 | 376 | 18 | 3 | EFO_0009332 | |
| Disease | white matter microstructure measurement | 1.61e-03 | 390 | 18 | 3 | EFO_0005674 | |
| Disease | gastroesophageal reflux disease | 1.71e-03 | 101 | 18 | 2 | EFO_0003948 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| STTTTVEIRKSSVMT | 156 | Q9H6B1 | |
| VEIRKSSVMTTEITS | 161 | Q9H6B1 | |
| SSVMTTEITSKVEKS | 166 | Q9H6B1 | |
| TTRRTETKVTKTVKT | 116 | O00192 | |
| ETKVTKTVKTVTTRT | 121 | O00192 | |
| TEKKMVSTVSELVTT | 531 | P13611 | |
| KRKTVITEVTTMTST | 1706 | Q12830 | |
| TMTSTVATESKTVIK | 1716 | Q12830 | |
| TMQERITTTKKGSIT | 341 | P06576 | |
| KEVTTVMTSDISKSS | 1771 | Q8WXI7 | |
| RMETTTTALKTTTTA | 10471 | Q8WXI7 | |
| MTTKNLETKVTVTSS | 1 | Q9H2G9 | |
| KISTVSKAMVTISNT | 1361 | Q2KJY2 | |
| VMETTTTMATTTTRK | 1286 | Q9Y4C0 | |
| TKETTTVIVTTTKSL | 256 | Q6ZSS7 | |
| EKIKSSMTQLSTTTV | 1856 | Q96QU1 | |
| LTTKNMEVSVATTTK | 3416 | P04114 | |
| TTVLTMTTLSTIARK | 291 | Q99928 | |
| TVLTMTTLSTIARKS | 311 | P18507 | |
| MITVRTKSSQSVKDV | 2281 | Q9BZC7 | |
| SSTIMRERKTRKTTS | 661 | Q9H159 | |
| RTETTVKKVVKTVTT | 136 | O60716 | |
| VMETTTTMATTTTRK | 281 | Q9HDB5 | |
| KTDVRRMSTSKVTVL | 116 | Q5FWF4 |